EFFECT OF INTRAVAGINAL PRASTERONE (DHEA) ON MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVOVAGINAL ATROPHY DUE TO MENOPAUSE, IN WOMEN UNDER TREATMENT WITH AN AROMATASE INHIBITOR FOR BREAST CANCER

Registry ID

ERC-260

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

ENDOCEUTICS INC

Last update

2019-01-18

Conditions

• VULVOVAGINAL ATROPHY

Related clinical trials

• THE USE OF VAGINAL PROGESTERONE VERSUS PLACEBO FOR THE TREATMENT OF VULVOVAGINAL ATROPHY-A DOUBLE BLIND RANDOMIZED CONTROL TRIAL.
• INTRAVAGINAL PRASTERONE (DHEA) AGAINST VULVOVAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE (PLACEBO CONTROLLED, DOUBLE BLIND AND RANDOMIZED PHASE III STUDY)

View on source registry